miR-451a/143-3p gene therapy

miR-451a/143-3p gene therapy has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 9, 2026: “Particles from exercised muscle reduced heart injury in mice”.

Intervention

1 paper studies it1 findingUpdated Nov 9, 2026

1 new paper in 30 daysSee all 1 papers on miR-451a/143-3p gene therapy

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

1 lab in 1 country

Animals1

What did studies of miR-451a/143-3p gene therapy find?

Studies of miR-451a/143-3p gene therapy measured one outcome, myocardial ischemia/reperfusion injury.

Myocardial ischemia/reperfusion injury

downin mice1

1 study

miR-451a/143-3p gene therapy protects against myocardial ischemia/reperfusion injury in mice (myocardial ischemia/reperfusion injury).
“Skeletal muscle-specific overexpression of miR-451a/143-3p recapitulated the cardioprotective effects of exercise in vivo.”
Animalsmyocardial ischemia/reperfusion injuryskeletal muscle-specific overexpressionheart
Particles from exercised muscle reduced heart injury in mice
Circulation researchNov 9, 2026

More on Myocardial ischemia/reperfusion injury

Latest

1 paper in 12 months

Circulation ResearchNov 9

Particles from exercised muscle reduced heart injury in mice

Mouse experiments tracked tiny packages released by skeletal muscle after four weeks of exercise and tested their role in limiting heart damage.Mouse experiments tracked tiny packages released by skeletal muscle after four weeks of exercise and tested their role in limiting heart damage.

Mouse studyExercise

Paper